Erectile Dysfunction and Neurological Comorbidities: a Contemporary Review

Purpose of ReviewThe goal of this article is to review the major neurologic disorders that can lead to erectile dysfunction (ED) as well as the current management options, highlighting the most recent literature on the subject.Recent FindingsStudies suggest that emerging novel therapies may act to supplement the established therapies for neurogenic ED, such as adipose tissue-derived mesenchymal stem cells and focal muscle vibration. Recent studies and meta-analyses also confirm the safety and efficacy of phosphodiesterase type-5 inhibitors (PDE5i) as the first-line therapy for neurogenic ED.SummaryNeurological conditions such as multiple sclerosis, Parkinson's disease, spinal cord injury, and stroke can have unique and multifactorial contributions to ED. PDE5i remain the mainstay of treatment for neurogenic ED. Non-pharmacological treatments are also available for patients who desire that option. A multidisciplinary approach is the most effective method of treatment.